Q2i's OARS software application moves to Phase II of National Institute of Health (NIH) clinical trial which will evaluate the application's efficacy in improving Opioid Use Disorder treatment
This comes after a successful Phase I trial and with over 1000 patients it's the largest trial of its kind in the country.
- This comes after a successful Phase I trial and with over 1000 patients it's the largest trial of its kind in the country.
- OARS is designed to increase patient engagement, program adherence, and MAT program availability as well as increasing treatment retention.
- UCLA is Q2i's academic partner for this project with Dr. Steven Shoptaw leading the research team that is evaluating the OARS software application.
- Dr. Shoptaw said, "The availability and access gap for OUD patients seeking treatment is a real issue that needs addressing.